Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic Breast Cancer Patients

To evaluate the patterns and treatment outcomes of pyrotinib plus trastuzumab and chemotherapy in the real world.

Completed

Looking for future studies?

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

woman, age > 18 years old
diagnosed with HER2 +Metastatic Breast Cancer
received pyrotinib plus trastuzumab and chemotherapy for at least one cycle, starting from 2018.07-2022.09
available medical history

Exclusion criteria

medical history was incomplete

Treatment and study plan

Primary outcomes

progression-free survival (PFS)

Time frame: 6 weeks

Progression free survival

Secondary outcomes

Adverse events

Time frame: 6 weeks

Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)

Sponsors and collaborators

Lead sponsor

Fudan University

Other

Registry information

Official study title

Pyrotinib Plus Trastuzumab and Chemotherapy in Metastatic HER2-positive Breast Cancer Patients- a Multicenter Retrospective Study

Important dates

Study start: 2022
Primary completion: 2023
Study completion: 2023
First posted: May 3, 2023
Registry last updated: May 3, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed